Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket

Gainers

• Biophytis S.A. (NASDAQ:BPTS) shares surged 53.9% to $3.31 in pre-market trading after the company signed a partnership with SEQENS to produce Sarconeos (BIO101) active compound, the company's main product.
• Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) shares gained 41.8% to $0.3729 in pre-market trading after EMA announced positive feedback on the company's proposed Phase 3 study AR-301 for pneumonia caused by Gram-positive bacteria Staphylococcus aureus in mechanically ventilated hospitalized patients.
• Karyopharm Therapeutics Inc. (NASDAQ:KPTI) rose 26.1% to $1.93 in pre-market trading after the company received FDA Fast Track Designation for Selinexor for Myelofibrosis.
• Rubicon Technologies, Inc. (NYSE:RBT) shares rose 19.9% to $0.47 in pre-market trading after surging 19% on Monday.
• Taoping Inc. (NASDAQ:TAOP) shares gained 14.4% to $0.5999 in pre-market trading after declining 7% on Monday.
• Vapotherm, Inc. (NYSE:VAPO) shares rose 13.4% to $0.4364 in pre-market trading after gaining 8% on Monday.
• Healthcare Triangle, Inc. (NASDAQ:HCTI) gained 13.4% to $5.26 in pre-market trading after jumping 27% on Monday.
• Hitek Global Inc. (NASDAQ:HKIT) rose 11.1% to $6.71 in pre-market trading.
• iSun, Inc. (NASDAQ:ISUN) shares climbed 10.4% to $0.4350 in pre-market trading.
• Near Intelligence, Inc. (NASDAQ:NIR) gained 9.3% to $1.86 in pre-market trading. Benchmark recently initiated coverage on the stock with a Speculative Buy rating and announced a $3 price target.

Losers

• 9 Meters Biopharma, Inc. (NASDAQ:NMTR) fell 59% to $0.2550 in pre-market trading after declining around 8% on Monday.
• Masimo Corporation (NASDAQ:MASI) fell 27.3% to $106.95 in pre-market trading after the company reported weak preliminary revenue results for the second quarter.
• CEL-SCI Corporation (NYSE:CVM) fell 22% to $2.23 in pre-market trading after the company priced its public offering of 2.5 million shares at $2 per share.
• ProMIS Neurosciences, Inc. (NASDAQ:PMN) shares dropped 18.1% to $5.07 in pre-market trading. ProMIS Neurosciences shares jumped 120% on Monday after the company presented preclinical data supporting the potential therapeutic advantage of its lead candidate for AD, PMN310, and additional studies that further characterize a computationally-derived AD vaccine at AAIC 2023.
• First Wave BioPharma, Inc. (NASDAQ:FWBI) fell 13.6% to $0.7001 in pre-market trading after declining around 15% on Monday.
• TC Biopharm (Holdings) Plc (NASDAQ:TCBP) shares fell 11.5% to $0.4130 in pre-market trading after declining around 10% on Monday.
• EUDA Health Holdings Limited (NASDAQ:EUDA) fell 11.4% to $0.54 in pre-market trading.
• Novan, Inc. (NASDAQ:NOVN) fell 11.1% to $0.16 in pre-market. Novan shares declined 70% on Monday after the company announced it entered into an agreement to sell substantially all of its assets and filed for Chapter 11 protection.
• Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) fell 9.5% to $8.80 in pre-market trading after reporting a proposed public offering of common stock.
• Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) shares fell 7.1% to $7.00 in pre-market trading. LIXTE Biotechnology shares jumped over 38% on Monday after the company announced results of its collaboration with the Netherlands Cancer Institute that showed LB-100 enhanced the effectiveness of immunotherapy and chemotherapy.

Now Read This: Market Volatility Increases Following China Data; S&P 500 Settles Higher